WO2026139841 - AROMATIC CARBOXAMIDE COMPOUNDS AND METHODS OF USING THEREOF

National phase entry is expected:
Publication Number WO/2026/139841
Publication Date 02.07.2026
International Application No. PCT/IB2025/063301
International Filing Date 22.12.2025
Title **
[English] AROMATIC CARBOXAMIDE COMPOUNDS AND METHODS OF USING THEREOF
[French] COMPOSÉS DE CARBOXAMIDE AROMATIQUE ET MÉTHODES D'UTILISATION DE CEUX-CI
Applicants **
NOVARTIS AG
Inventors
BEHNKE, Dirk
BUSSENAULT, Alex
D'ALESSANDRO, Pier Luca
DITTRICH, Birger
DOUMAMPOUOM-METOUL, Lionel
FISCHER, Christian
FURET, Pascal
GOMMERMANN, Nina
JEULIN, Ingrid Karen Jennifer
LANINI, Jessica
MACKAY, Angela Claire
MARCHAND, Jean-Rémy Thierry
MEYER, Arndt
PATORA-KOMISARSKA, Krystyna
SPANKA, Carsten Alfred Werner
STAUFFER, Frédéric
TEIXEIRA-FOUCHARD, Sylvie
VON MATT, Peter Josef
Priority Data
63/738,637   24.12.2024   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3957
EPO Filing, Examination, Granting28144
Japan Filing, Examination, Granting3136
South Korea Filing, Examination, Granting4229
USA Filing, Examination, Granting12240
MasterCard Visa
Total: 51,706
Contact Us
Abstract[English] The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein the variable are as defined herein. The invention further provides modulators or inhibitors of STAT6 activity, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-4 and/or IL-13.[French] La présente divulgation concerne un composé de Formule (I) ou un sel, hydrate, solvate, stéréoisomère ou tautomère pharmaceutiquement acceptable de celui-ci, les variables étant telles que définies dans la présente. L'invention concerne en outre des modulateurs ou inhibiteurs de l'activité de STAT6, des procédés pour leur préparation, des compositions pharmaceutiques et des médicaments les contenant, ainsi que leur utilisation dans des maladies et troubles médiés par l'IL-4 et/ou l'IL-13.